TANVEX BIOPHARMA, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.55 TWD | +1.28% |
|
-2.57% | -33.10% |
| 03-14 | Tanvex BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 02-06 | Tanvex BioPharma, Inc. Announces the Appointment of James Williamson as Accounting Officer | CI |
ETFs positioned on Tanvex BioPharma, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 7 M€ | +0.11% | - |
Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Companyâs product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.
Calendar
18/06/2024
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -33.10% | 220M | |
| +5.21% | 111B | |
| +11.38% | 105B | |
| -11.88% | 22.34B | |
| -3.52% | 21.93B | |
| -6.13% | 18.59B | |
| -36.52% | 18.12B | |
| -10.32% | 16.96B | |
| +4.09% | 13.7B | |
| +38.49% | 12.45B |
- Stock Market
- Equities
- 6541 Stock
- Funds and ETFs Tanvex BioPharma, Inc.
